October 7, 2019 PR-M10-19-NI-009
SAN DIEGO /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic approach successfully reduces rheumatoid arthritis in an animal model. The data disclosed today, which is the subject of a United States patent application, show that the Company's drug candidate induces activation of a type of immune system cell termed "T Regulatory Cells". The immunology community believes that T regulatory cells serve a fundamental role in protecting the body from uncontrolled inflammation or autoimmunity.
"The reduction of rheumatoid arthritis disease, which correlated with an increase in T regulatory cell numbers and a decrease in Th17 cells induced by the cannabidiol-based therapeutic drug mimics natural conditions in which autoimmunity goes into remission," said Thomas Ichim, PhD, Senior Advisor to the Company. "Similar changes in immunological parameters are seen in pregnancy, in which various autoimmune diseases are known to go into remission. We believe that we may have uncovered a new approach to autoimmunity that spares the patients the toxicity and side effects of non-specific immune suppression, which is the current treatment paradigm today."
Autoimmune diseases are conditions in which the immune system starts attacking components of the body. Major autoimmune conditions include rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and lupus.
"These current findings add another therapeutic candidate to our existing portfolio which centers of modulation of inflammatory pathways such as NR2F6," noted David Koos, Chairman and CEO of Regen BioPharma. "What this means to our small molecule drug development programs is CBD appears when used with other compounds to amplify the desired outcome. Our current pipeline of NR2F6 small molecules both augment and inhibit interleukin-17 production, we see potential synergy between today's disclosed data and our ongoing small molecule programs."
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
 Göschl et al. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol. 2019 May;41(3):301-314. https://link.springer.com/article/10.1007%2Fs00281-019-00741-8
SOURCE Regen BioPharma Inc.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders.